Issues › Prescription Drug Pricing
Prescription Drug Pricing
488 statements about Prescription Drug Pricing from 166 members since Jan 3, 2025.
Statements about Prescription Drug Pricing, last 12 weeks
DemRep● = 1 statement
Statements per week mentioning Prescription Drug Pricing, all members, split by party. Democrats stacked first, Republicans after, four to a row. Hover a dot for the member and headline; click a dot to search for that headline. Click a week to set the dates below. Aug 31, 2026 – Nov 22, 2026.
Most active on Prescription Drug Pricing · Aug 31 – Nov 22
- 1DJeanne ShaheenNH9
- 2RChuck GrassleyIA3
- 3DRichard J. DurbinIL2
- 4DPatty MurrayWA2
- 5DKim SchrierWA-082
- 6RRobert P. Bresnahan, Jr.PA-082
Click a name to open their profile. Count is statements, not channel copies.
All 488 statements
Newest first-
Introduced bill to lower prescription drug costs by expanding access to biosimilars.
“Skyrocketing prescription drug prices are causing too many Americans to have to choose between their life-saving medications and putting food on the table, especially seniors, communities of color, and the millions of people living on fixed incomes who need their prescriptions to live”
-
Shaheen, Collins Lead 243 Lawmakers in Pushing for Reauthorization of Special Diabetes Program
Led 243 lawmakers urging reauthorization of Special Diabetes Program before December 31 expiration.
“Congress has reauthorized these programs with bipartisan support on a regular basis since the programs’ inception in 1997.”
-
ICYMI: Shaheen Ramps Up Push for Bipartisan Bill Capping Insulin Costs in Lame Duck Session
Pushed for bipartisan INSULIN Act passage to cap monthly insulin costs at $35.
“But many Americans still struggle to afford insulin, according to diabetes advocacy organizations. A handful of groups, including the American Diabetes Association and the National Kidney Foundation, sent letters to the White House and to congressional leadership on Friday urging passage of the bill.”
-
Chaired hearing on prescription drug costs and bipartisan bills to lower prices.
“The interim reports are non-binding, but they gave great information and great insight. Like you said in your opening statement, we are waiting for the full report with legislative action that Congress can take.”
-
Murray Says Anti-Abortion Extremist Heidi Overton’s Nomination Will Go Nowhere
Opposed FDA nominee Heidi Overton's confirmation, citing anti-abortion extremism and medication abortion stance.
“We have decades of proof that medication abortion is safe and effective. Millions upon millions of women have used this medication. But in our hearing, Dr. Overton would not say what the science has said for years now: that the abortion pill is safe and effective.”
-
Highlighted health advocacy support for bipartisan INSULIN Act to cap insulin costs at $35 monthly.
“Voters sent a clear message this election that Congress needs to take urgent action to lower costs for American families”
-
Welch Pushes Bipartisan Bill to Lower Cost of Prescription Drugs, Streamline Drug Patent Litigation
Pushed bipartisan bill to lower prescription drug costs by streamlining patent litigation for generic drugs.
“My hope is that we’re going to be able to do some bipartisan legislation that focuses on competition; that takes away the manipulation of the patent system. Senator Hawley and I have the ETHIC Act which would essentially get rid of patent thickets”
-
Questioned witnesses about Medicare's authority to negotiate prescription drug costs during Senate Judiciary Committee hearing.
“How could this be good for the country, for more and more people to be uninsured?”
-
Grassley Opens Judiciary Hearing Examining Avenues to Make Prescription Drugs More Affordable
Held hearing examining competition and transparency to lower prescription drug costs.
“Prescribing Sunshine: How Competition & Transparency Lowers Prescription Drug Costs”
-
U.S. Senator Katie Britt Fighting to Bring Down Prescription Drug Costs
Questioned witnesses at Senate Judiciary Committee hearing on lowering prescription drug costs.
“We’ve supported the legislation that has already passed that has focused on PBMs and also support tackling vertical integration.”
-
Called for passage of bipartisan Drug-price Transparency for Consumers Act during Senate Judiciary Committee hearing.
“This hearing is going to make clear that our work to address the high cost of prescription drugs is far from over. Let’s work together, on a bipartisan basis, to do something to help families afford their prescription drugs.”
-
Warned against prediction markets allowing betting on clinical trials and drug approvals.
“We are concerned about a troubling development that prediction markets are now allowing individuals to bet on clinical trials and drug approvals.”
-
Bergman, Ruiz Introduce Bipartisan Bill to Preserve Critical Drug Discounts for Safety Net Providers
Introduced bipartisan bill to preserve prescription drug discounts for safety-net providers.
“Rural hospitals and community health centers across Northern Michigan and the Upper Peninsula are already operating on razor-thin margins. The last thing they need is another Washington mandate forcing them to pay more upfront for prescription drugs and then wait to get their money back.”
-
Praised Department of Labor rule requiring pharmacy benefit managers to disclose fees.
“Where there's mystery, there's margin, and PBMs have made a fortune off both”
-
MATSUI INTRODUCES BIPARTISAN LEGISLATION TO PROTECT PATIENT ACCESS TO AFFORDABLE MEDICATIONS
Introduced bipartisan bill to protect patient access to affordable medications through 340B program.
“The 340B program was created to ensure that patients, hospitals, and health centers have access to discounted medicines, not pad the profits of pharmacy benefit managers and insurance companies”
-
Introduced bipartisan bill to expand Medicare drug subsidy eligibility to Puerto Rico.
“Nuestra prioridad es atender lo básico, y la salud es básica. Miles de adultos mayores no pueden pagar sus medicinas.. Esta medida busca darles más dinero para sus medicamentos”
-
Urged FTC to complete pharmacy benefit manager investigation and release final recommendations.
“The two interim reports and proposed consent agreements provide substantial information, but they do not complete the study or provide a comprehensive set of recommendations.”
-
Joined healthcare leaders to discuss her bill capping insulin costs at $35 monthly for all Americans.
“Costs across the board are far too high for patients and families in Washington state. As a doctor with Type 1 diabetes, I was so proud to cap insulin at $35 a month for seniors a few years ago.”
-
Larsen, Colleagues Succeed in Delaying New CBP Rule Harming Access to Lower-Cost Medications
Praised Trump administration's delay of CBP rule that would restrict affordable prescription medication access.
“We are concerned that the new process could be implemented in a manner that prevents personal-use prescription medicines from being shipped to the United States or results in their routine refusal, including medicines Americans have long obtained from licensed pharmacies abroad.”
-
Highlighted bipartisan support for INSULIN Act to cap monthly insulin costs at $35.
“The INSULIN Act is an important step toward making insulin more affordable and strengthening safeguards for people who rely on it. We urge Congress to pass it this year.”
-
Introduced bipartisan bill to delay implementation of 340B drug rebate model.
“Families in Michigan are already struggling to pay for healthcare”
-
Op-Ed: Health care premiums continue to rise. Congress can lower them
Wrote op-ed calling for Congress to address rising health care premiums driven by drug costs.
-
Introduced bipartisan bill to delay 340B drug rebate model implementation to protect patient access.
“Patients and providers should not have to bear the risks of an untested change to a program that helps deliver affordable medicines to communities across the country”
-
Released video highlighting INSULIN Act and state gaps in insulin cost caps.
“Diabetes is a condition that touches the lives of so many Americans across the country, and the state you live in shouldn’t determine whether you can afford your life-saving insulin.”
-
Doggett Statement on New GAO Report on Insurer-Owned Pharmacies
Criticized insurers' preferential treatment of their own pharmacies in drug pricing.
“There is a real danger that consumers and taxpayers are being ripped off by giant health conglomerates. Three insurer-pharmacy benefit managers control 80% of prescription drug claims.”
Sources: members’ press releases from their official websites (since the 119th Congress began (Jan 3, 2025)) and the Congressional Record (since Aug 2026). Statements are tagged to Prescription Drug Pricing by AI reading of the full text. Quotes are shown only when they match the archived source text word for word.